Wendell-Lamar B. Blackwell

TL;DR: Knowing the structural differences between the two ACE domains should allow clinicians to envision new therapies for diseases not currently treated with ACE inhibitors, and these reagents will undoubtedly be powerful tools for probing the physiologic actions of each ACE domain.

TL;DR: The current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing are discussed, including BRAF V600E for vemurafenib in melanoma and ERBB2 (HER2/neu) for trastuzumab in breast cancer.

TL;DR: Recent studies examining the functional significance of ACE tissue-specific expression and the presence in ACE of two independent catalytic sites with distinct substrates and biological effects explain why ACE makes important contributions to many different physiological processes including renal development, blood pressure control, inflammation, and immunity.

TL;DR: The presence of ACE in renal tissue facilitates angiotensin II accumulation, GFR reductions, and changes in the expression levels and post-translational modification of sodium transporters that are obligatory for sodium retention and hypertension in response to nitric oxide synthesis inhibition.

TL;DR: Application of recent developments in nanoemulsion and polymeric micelle for targeted delivery and drug release are models of dosage optimization, increasing efficacy and improving outcomes in these major eye diseases.